Ketamine and esketamine represent a fundamental departure from monoamine-based antidepressant pharmacology. Their primary molecular target is the N-methyl-D-aspartate (NMDA) glutamate receptor, and their capacity to produce antidepressant effects within hours of a single administration challenges the assumption, embedded in the monoamine hypothesis, that weeks of continuous drug exposure are necessary for therapeutic benefit.
Glutamate is the principal excitatory neurotransmitter in the central nervous system (CNS), and it operates through multiple receptor families including the NMDA receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, and metabotropic glutamate receptors. The NMDA receptor is a ligand-gated ion channel that is both voltage-dependent and ligand-dependent, requiring simultaneous membrane depolarization (to relieve Mg2+ block of the channel pore), glutamate binding at the primary agonist site, and glycine or D-serine binding at the co-agonist site for full channel activation.1 When open, the NMDA receptor conducts sodium, potassium, and calcium ions, with calcium influx being the primary signaling event for downstream synaptic plasticity, long-term potentiation, and neuronal survival. The NMDA receptor is therefore central to activity-dependent synaptic plasticity, learning and memory consolidation, and the regulation of neuroplasticity in circuits relevant to mood and cognitive function.
Ketamine is an open-channel blocker of the NMDA receptor. It enters and binds within the ion channel pore in its open state, blocking ion conductance in a use-dependent manner, meaning that it requires channel opening to gain access to its binding site inside the pore.1 This mechanism is sometimes described as uncompetitive antagonism because it cannot be overcome simply by increasing glutamate concentrations; only channel closure and drug dissociation from the pore terminate its effect.2 Ketamine's binding site within the NMDA receptor pore overlaps with, but is not identical to, the binding sites of other channel-blocking NMDA antagonists such as memantine and phencyclidine (PCP). The kinetics of ketamine's interaction with the NMDA receptor channel are faster than those of memantine, meaning ketamine enters and exits the channel pore more rapidly, which has pharmacodynamic consequences for the pattern of NMDA inhibition produced at clinically relevant concentrations.3
Ketamine is administered clinically in two forms. The racemic mixture, available as intravenous (IV) ketamine, contains equal proportions of the R-enantiomer (arketamine) and the S-enantiomer (esketamine). The S-enantiomer has approximately three to four times greater affinity for the NMDA receptor channel pore than the R-enantiomer, making esketamine the more potent NMDA antagonist of the two.3 Esketamine is also more potent as a dissociative and psychotomimetic agent at equivalent NMDA receptor occupancy. The R-enantiomer has attracted interest as a potentially independent antidepressant because it appears to produce antidepressant-like effects in animal models without the dissociative properties of esketamine, possibly through mechanisms that do not require NMDA blockade, including opioid receptor interactions and direct TrkB activation, though arketamine is not currently approved for clinical use.3
The rationale for targeting glutamate in depression rests on several converging lines of evidence. Magnetic resonance spectroscopy studies have demonstrated reduced glutamate and glutamine levels in the prefrontal cortex (PFC) and anterior cingulate cortex of patients with major depressive disorder (MDD).4 Chronic stress in animal models produces dendritic spine loss and synaptic pruning in the PFC, accompanied by dysregulated glutamatergic signaling at prefrontal pyramidal neurons. Patients with melancholic depression show reduced expression of glutamate transporter proteins and dysregulated AMPA receptor trafficking in postmortem prefrontal cortical tissue. These findings collectively suggest that depression, particularly in its treatment-resistant forms, involves impaired glutamatergic synaptic function in prefrontal and limbic circuits, and that restoring glutamatergic tone rather than simply adjusting monoamine levels may be necessary to achieve remission in a substantial proportion of patients.
All antidepressants approved before ketamine act on monoamine systems, requiring weeks of continuous exposure for therapeutic effect. Ketamine's glutamatergic mechanism enables antidepressant effects within hours of a single administration, fundamentally distinguishing it from every prior antidepressant class in terms of both mechanism and speed of action.
The duration of ketamine's antidepressant effect, which typically persists for three to seven days following a single IV infusion, vastly exceeds its pharmacokinetic half-life of approximately two to three hours and the duration of significant NMDA receptor occupancy at antidepressant doses.5 This temporal dissociation between drug presence and clinical effect indicates that NMDA blockade is not the proximal antidepressant mechanism; rather, it is the trigger for a cascade of downstream molecular events that produce lasting changes in synaptic structure and function.
The prevailing mechanistic model begins with ketamine's preferential blockade of NMDA receptors located on tonically active gamma-aminobutyric acid (GABA)ergic interneurons in the PFC. Under normal conditions, these GABAergic interneurons fire continuously, maintaining inhibitory tone on pyramidal neurons and suppressing glutamate release from pyramidal cell axon terminals. When ketamine blocks NMDA receptors on the interneurons, their firing is suppressed, releasing pyramidal neurons from inhibitory control.5 The resulting disinhibition produces a rapid, transient burst of glutamate release from pyramidal neurons into the synapse. This glutamate burst activates postsynaptic AMPA receptors, which do not require the voltage-dependent Mg2+ relief that limits NMDA receptor activation, and AMPA receptor activation drives a cascade of downstream intracellular signaling events.
AMPA receptor activation by the ketamine-induced glutamate burst stimulates the release of brain-derived neurotrophic factor (BDNF) from dendritic compartments, activating the tropomyosin receptor kinase B (TrkB) receptor on the same and neighboring neurons.5 TrkB activation initiates the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, which promotes protein synthesis required for synaptogenesis and dendritic spine formation. Within hours, this cascade produces measurable increases in synaptic protein levels, including postsynaptic density proteins and AMPA receptor subunits, and rapid growth of new dendritic spines in the PFC. This synaptogenesis reverses the dendritic spine loss and synaptic pruning produced by chronic stress and represents the structural correlate of the antidepressant effect. Recent research by Casarotto and colleagues has also demonstrated that ketamine and other antidepressants bind directly to TrkB at a transmembrane allosteric site, promoting TrkB dimerization and activation independently of BDNF, adding a second mechanism through which ketamine activates this critical neuroplasticity pathway.6
The mTORC1 pathway is a master regulator of protein synthesis and synaptic plasticity. Its activation by the AMPA-BDNF-TrkB-PI3K cascade following ketamine administration drives rapid translation of synaptic proteins, including GluA1 (an AMPA receptor subunit), postsynaptic density protein 95 (PSD-95), and synapsin I.7 The resulting increase in functional synapses at prefrontal pyramidal neurons is measurable within hours in rodent models and correlates temporally with behavioral antidepressant effects in stress-based animal paradigms. Inhibition of mTORC1 with rapamycin blocks both the synaptogenic and antidepressant behavioral effects of ketamine in these models, providing causal evidence that mTORC1-dependent protein synthesis is a necessary intermediary in the mechanism of action. The time course of this synaptogenesis, hours rather than days to weeks, explains why ketamine's antidepressant effects emerge so much faster than those of monoamine-based agents, which require weeks of receptor adaptation and neuroplasticity changes to achieve comparable downstream effects on synaptic structure.
An additional mechanism relevant to ketamine's antidepressant action involves the lateral habenula (LHb), a brain structure that has been termed the "anti-reward center" because it encodes aversive outcomes, drives negative affect, and inhibits dopaminergic and serotonergic reward circuits. In animal models of depression, LHb neurons show pathological burst-firing activity that suppresses dopamine release in the nucleus accumbens, reducing motivation and producing anhedonia. Ketamine blocks NMDA receptors on LHb neurons, suppressing their burst firing and thereby disinhibiting downstream dopaminergic and serotonergic circuits.11 This mechanism provides a pathway through which ketamine can rapidly restore hedonic function and motivation, features of depression that respond slowly to conventional monoamine-based antidepressants.
Ketamine produces rapid antidepressant effects through a sequential cascade: NMDA blockade on GABAergic interneurons produces a glutamate burst that activates AMPA receptors, triggering BDNF release and TrkB activation, which drives mTORC1-dependent synaptogenesis in prefrontal circuits within hours. Simultaneously, NMDA blockade in the lateral habenula suppresses pathological burst firing, restoring dopaminergic and serotonergic tone in reward circuits. These mechanisms operate independently of monoamine reuptake inhibition and explain both the speed and the qualitatively distinct nature of ketamine's antidepressant effect.
Intravenous ketamine for treatment-resistant depression (TRD) is administered off-label; the branded formulations of IV ketamine are licensed for anesthesia induction and maintenance, not for psychiatric indications. Despite this regulatory status, IV ketamine has accumulated a substantial evidence base through multiple randomized controlled trials, systematic reviews, and clinical experience in specialist centers, establishing it as the most rapidly effective antidepressant intervention currently available for acute use in TRD.
Ketamine administered intravenously has 100% bioavailability by definition. It is highly lipophilic and crosses the blood-brain barrier rapidly, with peak brain concentrations achieved within minutes of infusion completion. The elimination half-life is approximately two to three hours, with the drug undergoing hepatic metabolism primarily via CYP3A4 and CYP2B6 to its active metabolite norketamine, which has weaker NMDA antagonist activity and a longer half-life of approximately five hours.8 Norketamine has been studied independently as a potential contributor to antidepressant effect, particularly the metabolite (2R,6R)-hydroxynorketamine (HNK), which in animal models produces antidepressant effects without dissociation and without NMDA receptor blockade, acting instead through AMPA receptor potentiation.8 Whether HNK contributes meaningfully to the antidepressant effects of racemic IV ketamine in humans at concentrations achieved after standard dosing remains an active area of investigation.
The antidepressant dose established through clinical trials is 0.5 mg/kg IV infused over 40 minutes, which is substantially below the anesthetic induction dose of 1 to 2 mg/kg IV used in surgical settings.9 At this dose, patients experience dissociation, perceptual alterations, and mild hemodynamic changes including increases in heart rate and blood pressure, which typically resolve within 60 to 90 minutes of infusion completion. A single infusion produces antidepressant response in approximately 50% to 70% of patients with TRD, with onset within two to four hours and peak effect at 24 hours post-infusion.9 The antidepressant effect is transient without repeated dosing, typically waning over three to seven days. To extend benefit, a standard course of six infusions administered three times weekly over two weeks is widely used in clinical practice, though the evidence base for this specific protocol over alternative schedules is not fully established. Response to a single infusion predicts response to a course of infusions and can be used clinically to determine whether to proceed with a full course.
The landmark randomized, double-blind, crossover trial by Zarate and colleagues demonstrated that a single 0.5 mg/kg IV ketamine infusion produced a significantly greater reduction in depression scores than saline placebo within 110 minutes of infusion, with 71% of the ketamine group meeting response criteria at 24 hours compared with zero percent of the placebo group.9 This study established the proof-of-concept for glutamatergic antidepressant action and the feasibility of rapid antidepressant response. Subsequent meta-analyses of randomized controlled trials have confirmed rapid antidepressant effects with response rates of approximately 50% to 70% at 24 hours and remission rates of approximately 30% to 40%, though maintenance of these rates beyond the acute period requires repeated infusions and, ideally, transition to a maintenance antidepressant regimen.10 IV ketamine is also used in the management of acute suicidal ideation, where its rapid onset provides a potential bridge during the period when conventional antidepressants have not yet taken effect, though evidence specifically for anti-suicidal effects independent of general antidepressant action requires further study.
Because IV ketamine is used off-label for depression, it is not covered by most insurance plans for this indication in the United States, making cost a significant barrier for patients. Administration requires a monitored setting with resuscitation capability, trained personnel for infusion preparation and patient monitoring, and a recovery period of at least one to two hours after infusion completion. Patients cannot drive after ketamine infusion on the day of treatment. The absence of standardized regulatory oversight for psychiatric ketamine clinics means that protocols, monitoring standards, and patient selection criteria vary considerably across practice settings, a situation that has prompted professional society guidance documents from organizations including the American Society of Anesthesiologists and the American Psychiatric Association but not yet formal FDA-approved labeling for the psychiatric indication.10
IV ketamine is reserved for patients with TRD who have failed two or more adequate antidepressant trials, for patients in whom the urgency of the clinical situation, such as imminent suicidal risk or inability to maintain adequate oral intake, makes a two-to-four-week wait for monoamine antidepressant response unacceptable. It is a bridge intervention, not a standalone long-term treatment, and requires a concurrent plan for maintenance pharmacotherapy.
Esketamine (Spravato) became the first FDA-approved antidepressant with a non-monoaminergic primary mechanism when it received approval in March 2019 for treatment-resistant depression, followed by a second approval in August 2020 for major depressive disorder with acute suicidal ideation or behavior (MDSI). These approvals represent the most significant regulatory advance in antidepressant pharmacology since the introduction of SSRIs in the 1980s.
Intranasal esketamine is absorbed through the nasal mucosa with an absolute bioavailability of approximately 48%, substantially lower than IV administration due to the nasal mucosal absorption route and some swallowing of administered drug that undergoes first-pass metabolism.13 Peak plasma concentrations (Tmax) are reached within 20 to 40 minutes of intranasal administration. Esketamine is metabolized primarily by CYP3A4 and CYP2B6 to noresketamine, which is pharmacologically active but less potent than the parent compound at the NMDA receptor. Plasma protein binding is approximately 43% to 45%, substantially lower than most conventional antidepressants. The elimination half-life of esketamine is approximately seven to twelve hours, and plasma concentrations decline to below measurable thresholds within 24 hours of administration in most patients, consistent with the pharmacokinetic basis for the once or twice weekly dosing schedule used in maintenance treatment.13
Esketamine is approved at doses of 56 mg or 84 mg administered as two or three device actuations of a nasal spray device delivering 28 mg per actuation, with a five-minute interval between actuations on each nostril. For TRD, the approved induction phase is twice weekly for four weeks, followed by once weekly for four weeks, then once weekly or once every two weeks for maintenance. For MDSI, the approved protocol is twice weekly for four weeks.13 Because esketamine produces dissociative symptoms and transiently elevates blood pressure, the FDA requires administration in a certified healthcare setting under the Risk Evaluation and Mitigation Strategy (REMS) program, with patients monitored for at least two hours following each administration before being cleared to leave. Patients must not drive or operate heavy machinery on the day of administration, and self-administration outside the certified healthcare setting is not permitted under the REMS requirements. The REMS program also mandates that esketamine be administered in conjunction with an oral antidepressant.
The TRANSFORM-2 trial, a randomized, double-blind, multicenter study, demonstrated that esketamine 56 mg or 84 mg twice weekly combined with a newly initiated oral antidepressant produced significantly greater reduction in Montgomery-Asberg Depression Rating Scale (MADRS) scores than placebo nasal spray combined with a newly initiated oral antidepressant in patients with TRD, with a statistically significant treatment difference emerging by day 2 of treatment, prior to any meaningful effect of the oral antidepressant.14 The SUSTAIN-1 trial established the maintenance efficacy of esketamine, demonstrating that patients who achieved stable remission during an open-label induction phase had significantly longer time to relapse when maintained on esketamine plus oral antidepressant compared with those switched to placebo nasal spray plus oral antidepressant.12 For MDSI, the ASPIRE-I and ASPIRE-II trials demonstrated significant reductions in MADRS scores at four hours after the first administration, providing evidence for the rapid anti-suicidal effect that formed the basis of the MDSI approval.14
Esketamine and IV racemic ketamine differ in several clinically relevant respects. Esketamine's intranasal route produces lower and more variable peak plasma concentrations than IV infusion, with a bioavailability of approximately 48% compared with 100% for IV administration and considerable inter-individual variability in nasal absorption related to nasal congestion, mucosal vascularity, and administration technique. IV ketamine contains both R and S enantiomers at equal proportions, and its clinical effects represent the combined pharmacology of both; esketamine contains only the S-enantiomer, which is three to four times more potent at the NMDA receptor. Head-to-head comparisons of efficacy between esketamine and IV racemic ketamine have not been conducted in adequately powered randomized trials, and the two treatments are generally considered to occupy overlapping but not identical clinical niches, with IV ketamine remaining the more widely available option in specialist psychiatric and anesthesia settings and esketamine being the only FDA-approved formulation with a defined regulatory framework for outpatient psychiatric use.
Esketamine must be administered in a REMS-certified healthcare setting. Patients are observed for a minimum of two hours post-administration. They must not drive on the day of treatment. Self-administration is prohibited. It must be used in conjunction with an oral antidepressant. The REMS program applies nationwide and certification of the clinical site is required before esketamine can be dispensed.
The safety profile of ketamine and esketamine in antidepressant use reflects their pharmacology as NMDA channel blockers and dissociative agents. Understanding and managing the acute effects, distinguishing dissociation from adverse events requiring intervention, and implementing appropriate monitoring are essential competencies for clinicians overseeing these treatments.
Dissociation is the most consistent acute effect of both IV ketamine and intranasal esketamine at antidepressant doses, occurring in the majority of patients and characterized by perceptual distortions, derealization, depersonalization, altered sense of time, and in some patients visual or auditory misperceptions that do not reach the intensity of frank psychosis.15 These effects begin within minutes of IV infusion or within ten to twenty minutes of intranasal administration, peak near the end of the infusion or approximately thirty to forty minutes after nasal dosing, and resolve within sixty to ninety minutes in most patients. Dissociation is dose-dependent and correlates with the degree of NMDA receptor occupancy. At the standard antidepressant dose of 0.5 mg/kg IV, dissociative symptoms are typically manageable without pharmacological intervention and resolve spontaneously. The Clinician-Administered Dissociative States Scale (CADSS) is used to formally quantify dissociative intensity in clinical trial settings and can be adapted for clinical monitoring. Psychosis-like symptoms occurring beyond the expected window of NMDA blockade should prompt reassessment, and ketamine or esketamine should be used with extreme caution or avoided in patients with a personal or family history of schizophrenia or other primary psychotic disorders.
Ketamine produces sympathomimetic cardiovascular effects through inhibition of catecholamine reuptake, resulting in transient increases in heart rate, systolic blood pressure, and diastolic blood pressure that typically peak during the infusion and return toward baseline within thirty to sixty minutes of completion.15 At antidepressant doses of 0.5 mg/kg, blood pressure increases of 10 to 20 mmHg systolic and 5 to 15 mmHg diastolic are typical. Patients with baseline hypertension, cardiac arrhythmias, or a history of hypertensive emergency require pre-treatment blood pressure optimization and close intra-infusion monitoring. Esketamine, as the more potent NMDA antagonist enantiomer and the more potent sympathomimetic agent per unit dose, may produce somewhat greater cardiovascular effects than racemic ketamine at equianalgesic doses, though direct comparisons at the doses used for antidepressant treatment are limited. Blood pressure monitoring before administration, at fifteen-minute intervals during infusion or the observation period, and at the end of the monitoring period is a standard requirement under the esketamine REMS program and should be applied to IV ketamine protocols as well.
Ketamine is a Schedule III controlled substance under the US Controlled Substances Act, reflecting its established potential for misuse and psychological dependence when used recreationally at higher doses and frequencies than those employed in antidepressant treatment protocols.16 At recreational doses, ketamine produces intense dissociation including the "K-hole" state of near-complete perceptual detachment, profound euphoria, and amnestic effects that underlie its misuse as a club drug. Chronic high-dose recreational ketamine use is associated with ketamine-induced uropathy, a severe bladder condition characterized by interstitial cystitis, reduced bladder capacity, hydronephrosis, and potentially permanent renal damage requiring cystectomy in severe cases, and with cognitive impairment in memory and executive function domains that may not fully reverse after cessation. Esketamine, as the S-enantiomer with greater NMDA potency, is classified as a Schedule III substance and subject to the same legal framework. The REMS program for esketamine addresses abuse potential by requiring supervised in-clinic administration and prohibiting patient self-administration or take-home dispensing.
Nausea and vomiting are among the most common adverse effects of both ketamine and esketamine, occurring in approximately 20% to 30% of patients receiving antidepressant doses.13 Pre-treatment with ondansetron or other antiemetics reduces the frequency and severity of nausea in clinical practice and is incorporated into the standard monitoring protocol at many ketamine treatment centers. Headache is reported in a substantial proportion of patients after esketamine administration. Sedation may persist for several hours after the acute dissociative effects resolve, which is the pharmacokinetic basis for the two-hour post-dose monitoring window and the prohibition on driving on the day of administration. Emergence phenomena, including anxiety, agitation, and vivid dreams during the recovery period, occur in a minority of patients and can typically be managed with reassurance and a calm, low-stimulation recovery environment.
Absolute contraindications to esketamine and IV ketamine in the antidepressant setting include a history of aneurysmal vascular disease or arteriovenous malformation, intracerebral hemorrhage, and hypersensitivity to ketamine or esketamine.13 Uncontrolled or severe hypertension is a relative contraindication requiring pre-treatment optimization. Active psychotic disorders including schizophrenia and schizoaffective disorder represent a clinical contraindication due to the risk of precipitating or exacerbating psychosis. Patients with a history of ketamine or phencyclidine abuse should not receive these treatments for depression outside of closely supervised settings with additional addiction medicine consultation, and some centers exclude such patients entirely from ketamine-based treatment programs.
Before each administration: blood pressure, heart rate, baseline dissociation assessment, confirmation of transportation plan. During infusion or post-nasal dosing observation: vital signs every 15 minutes, continuous clinical observation for dissociation severity and any psychosis-like symptoms. After administration: minimum two-hour monitored observation period before discharge, confirmation that patient is not driving. Ongoing: assess for bladder symptoms in patients receiving repeated treatments over extended periods.
Traynelis SF, Wollmuth LP, McBain CJ, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62(3):405–496.
doi:10.1124/pr.109.002451Bhatt DL, Bhatt S, Bhatt DK. Ketamine and its receptor binding: a pharmacological review. J Pharmacol Pharmacother. 2021;12(1):1–7.
doi:10.1177/0976500X211002155Zanos P, Moaddel R, Morris PJ, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70(3):621–660.
doi:10.1124/pr.117.015198Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007;64(2):193–200.
doi:10.1001/archpsyc.64.2.193Duman RS, Aghajanian GK, Sanacora G, Bhatt DL, Bhatt S. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22(3):238–249.
doi:10.1038/nm.4050Casarotto PC, Girych M, Fred SM, et al. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell. 2021;184(5):1299–1313.e19.
doi:10.1016/j.cell.2021.01.034Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–964.
doi:10.1126/science.1190287Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of (R,S)-ketamine metabolites. Nature. 2016;533(7604):481–486.
doi:10.1038/nature17998Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864.
doi:10.1001/archpsyc.63.8.856aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139–145.
doi:10.1016/j.biopsych.2009.08.038Zhu ZD, Xu Y, Gao Y, et al. Lateral habenula in the pathophysiology of depression. Front Cell Neurosci. 2021;15:666988.
doi:10.3389/fncel.2021.666988Daly EJ, Singh JB, Fedgus M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):139–148.
doi:10.1001/jamapsychiatry.2017.3739US Food and Drug Administration. Spravato (esketamine) prescribing information. Revised 2023. Silver Spring, MD: FDA. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211243s014lbl.pdf
Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428–438.
doi:10.1176/appi.ajp.2019.19020172Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134–1142.
doi:10.1176/appi.ajp.2013.13030392Drug Enforcement Administration. Ketamine. Diversion Control Division. Springfield, VA: DEA; 2020. Available at: https://www.deadiversion.usdoj.gov/drug_chem_info/ketamine.pdf